Identity
CagriSema denotes coadministration of cagrilintide and semaglutide, not a single peptide.
Selected study only; not a complete clinical review.
Peptide library
CagriSema
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
The large phase III trial supports the studied coadministration regimen. Treatment-policy and on-treatment estimates differ. It does not demonstrate the quality, stability or safety of a self-mixed two-vial stack.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
3,417 adults without diabetes; randomized 68-week phase 3a trial.
What the sources found
Treatment-policy weight change was −20.4% with the combination versus −3.0% with placebo.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
CagriSema denotes coadministration of cagrilintide and semaglutide, not a single peptide.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Reported adverse effects
- Gastrointestinal events affected 79.6% versus 39.9% with placebo and were mainly transient and mild-to-moderate.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Human trials
This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
Treatment-policy weight change was −20.4% with the combination versus −3.0% with placebo.
Selected study only; not a complete clinical review.
Adverseeffects
Gastrointestinal events affected 79.6% versus 39.9% with placebo and were mainly transient and mild-to-moderate.
Selected study only; not a complete clinical review.
References
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. 2025.
PMID: 40544433
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.